GlaxoSmithKline migraine headache brand Excedrin continues its everyday headache cultural marketing, agreeing to help pay for a Cleveland Brown's perfect…
Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread.
For the second straight week, there’s a new psoriatic arthritis drug on the block.
Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.
Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise—but the Dublin drugmaker’s CEO isn’t too concerned.
Created by Janssen along with the American Cancer Society, Cancer Support Community and CancerCare, the website was years in the making.
GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.
Pharma TV ad spending has already officially topped last year with a total of $3.2 billion through the end of November, according to iSpot.tv data.
J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.
AbbVie and Roche are working to widen Venclexta’s patient population in previously treated chronic lymphocytic leukemia, and new data should help.